Targeting RAS - will GPR31 deliver us a new path forward?

Nicole Fehrenbacher; Mark R Philips

doi:10.1080/23723556.2017.1359228

Targeting RAS - will GPR31 deliver us a new path forward?

Mol Cell Oncol. 2017 Jul 31;4(6):e1359228. doi: 10.1080/23723556.2017.1359228. eCollection 2017.

Authors

Nicole Fehrenbacher¹, Mark R Philips¹

Affiliation

¹ Perlmutter Cancer Center, New York University School of Medicine, New York, NY.

Abstract

Effective anti-rat sarcoma viral oncogene (RAS) therapies have remained the holy grail of cancer treatment. Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) sustains tumorigenesis when linked to the plasma membrane (PM). The G protein-coupled receptor 31 (GPR31) is now identified to mediate KRAS membrane association and is crucial for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells, suggesting that GPR31 is a druggable target for anti-RAS therapy.

Keywords: Cancer; G-protein coupled receptor 31; GPR31; KRAS; RAS; anti-RAS therapy; cancer therapy.